Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. It is developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company is evaluating nebulized ensifentrine in its Phase III clinical program ENHANCE for COPD maintenance treatment. Its product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the phosphodiesterase 3 and 4 (PDE3 and PDE4) enzymes, which is designed to act as both a bronchodilator and an anti-inflammatory agent. The Company’s two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company’s wholly owned subsidiary is Verona Pharma, Inc.